Tuesday, February 27, 2007
A group of healthcare experts have published a series of six essays in the British medical journal Lancet discussing direct-to-consumer (DTC) advertising and what they see as the ‘Medicalizing’ of modern society. HealthDay Reporter Ed Edelson explores the issue in a well-balanced piece published yesterday at HealthDay News.
Princeton, N.J.-based PharmaNet Development Group is showing more signs of positive change as it attempts to move forward after troubled times. It announced this week that it appointed Johane Boucher-Champagne president and chief executive of its Anapharm unit, a phase I and bioequivalencey business based in Quebec City, Canada.
Where should Big Pharma’s next leaders come from?
Big Pharma Collaborates for Inter-Company Auditing Agreement
In line with the banner year shared by much of clinical trials industry, the Dublin, Ireland-based contract research organization (CRO) ICON reported big gains in 2006. The company generated $129 million in net revenue, a 46% increase compared with $88.1 million during the same period in 2005. The company had full year revenues of $455.6 million in 2006 compared with $342.8 million in 2005, representing an increase of 33%. ICON’s operating income rose 69% to $51.9 million in 2006 compared with $30.8 million in 2005.